로딩 중…
지수 로딩 중…
Curocell
372320· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩29,200-5.81%
2026-06-19
Price Chart
Curocell-5.65%
Financials
No data
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 444.60B KRW |
| Revenue | 0 KRW |
| Net Income | -48.20B KRW |
| Total Assets | 100.76B KRW |
| Net Assets | 24.53B KRW |
| Employees | 126 |
| Value | |
| P/B | 18.12x |
| FCF Yield | -6.82% |
| Profitability | |
| ROE | -196.50% |
| ROA | -47.84% |
| Financial Health | |
| Debt Ratio | 310.74% |
| Total Debt | 46.41B KRW |
| FCF | -30.31B KRW |
| Cash | 4.00B KRW |
| Current Ratio | 0.36x |
| Performance | |
| 1Y Return | -5.65% |
| 1M Return | -16.93% |
| From 52W High | -55.76% |
| 1Y MDD | -58.00% |
| Trading | |
| Volume | 84,322 shares |
| Foreign Own. | 1.51% |
| Per Share | |
| EPS | -3,336 KRW |
| BPS | 1,628 KRW |
Company Info
Qurocell was established in 2016 as a specialized enterprise for CAR-T therapeutic agent development and listed on the KOSDAQ market in 2023. The company holds several new drug pipelines, including CD19 CAR-T therapeutic agents, and completed clinical trials for Limcato, which applies OVIS™ CAR-T technology. Aiming for a 2025 product launch, it completed a manufacturing facility and applied for product approval in 2024, while also exploring expanded development for various cancer types and overseas market entry. Qurocell is headquartered in Yuseong-gu, Daejeon Metropolitan City.